With FDA approval of an investigational device exemption, J&J’s soft tissue robot moves a step closer to challenging ...

Medtronic Plc is a ... Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and ...

Medtronic announced today that it appointed Dr. Matthew Kroh as chief medical officer for Advanced and General Surgical Technologies.

Secondly, Medtronic's growth areas, including diabetes, electrophysiology, and surgical robotics, are seen as well-positioned ...

Medtronic is modestly undervalued based on DCF analysis, but slow revenue growth limits upside potential. Read why I ...

A new medical technology fund which focusses on early-stage health technologies is itself an innovation. Utilizing its ...

Medtronic plc MDT is scheduled to report second-quarter fiscal 2025 results on Nov. 19, before the opening bell. In the last reported quarter, the company’s adjusted earnings of $1.23 exceeded the ...

This growth is primarily driven by the rising prevalence of cardiovascular diseases (CVDs) worldwide, alongside continuous ...

Secondary outcomes through 6 months were reported from the VenaSeal Spectrum Surgical Stripping study, a randomized ...

(You can read the full research report on JPMorgan Chase here >>>) Medtronic’s shares have gained +8.3% over the year-to-date period against the Zacks Medical - Products industry’s gain of +12.0%.